Introduction {#Sec1}
============

Since the 1950s, the numbers of diagnostic radiographic studies and image-guided interventional procedures have steadily increased \[[@CR1]\]. In 2004, these diagnostic and therapeutic studies were the largest source of man-made radiation exposure and contributed to about 14 % of the total worldwide exposure from man-made and natural sources \[[@CR2]\]. The consequences of radiation, described as deterministic and stochastic effects, are of major concern \[[@CR3], [@CR4]\]. Following the "as low as reasonably achievable" (ALARA) principle, there is a balance between dose reduction and maintaining image quality at a diagnostic level \[[@CR5]\].

Transarterial chemoembolization (TACE) has become an important treatment option for a number of primary and secondary liver malignancies \[[@CR6]--[@CR10]\]. In most patients, TACE is performed repeatedly because of the multifocal nature of the disease, incompletely treated lesions or disease recurrence. This exposes both patients and clinical staff to high doses of ionizing radiation \[[@CR11]\].

A new X-ray imaging platform (AlluraClarity; Philips Healthcare, Best, Netherlands) which incorporates optimized acquisition parameters and several real-time image processing algorithms with the goal to reduce radiation exposure while maintaining diagnostic image quality was recently made available. In the scope of diagnostic and interventional neuroradiological procedures, this new platform showed a significant radiation exposure reduction of 60 % for the whole procedure and of 75 % for digital subtraction angiography (DSA) without a decrease in image quality \[[@CR12], [@CR13]\]. In comparison to neuroradiological procedures, TACE requires a higher tube current due to the larger field of view and body volume that needs to be passed by the X-ray photons, resulting in a higher radiation exposure in the same amount of time. In addition, abdominal procedures are more prone to motion artefacts, which could limit the applicability of the real-time image processing algorithms of the new imaging platform. Furthermore, the previously mentioned neuroradiological studies evaluated only two-dimensional imaging (digital fluoroscopy (DF) and DSA), and no three-dimensional imaging, such as cone beam computed tomography (CBCT), which is often performed during TACE procedures \[[@CR14]\].

The purpose of our study was to quantify the reduction of radiation that liver cancer patients are exposed to during transarterial chemoembolization (TACE) while maintaining diagnostic image quality, using a new C-arm imaging platform.

Materials and methods {#Sec2}
=====================

Study cohort {#Sec3}
------------

This prospective, single-institution, two-arm study was conducted in compliance with the Health Insurance Portability and Accountability Act and was approved by the institutional review board. In January and February 2014, 26 consecutive patients with primary or secondary liver cancer treated with TACE at our institution using the C-arm system (Allura Xper FD20, Philips Healthcare, Best, the Netherlands) available at that time were included (control group). The imaging platform was then upgraded to the new platform (AlluraClarity) and a second cohort of 52 consecutive patients between March and June 2014 with liver cancer treated with TACE (study group) was included. Thus the final population included a total of 78 patients.

MR imaging technique {#Sec4}
--------------------

All patients underwent baseline MR imaging approximately 2 weeks before intra-arterial treatment (mean 16 days, range 0--40) using a 1.5-T MRI unit (Magnetom Avanto, Siemens Medical Solutions, Forchheim, Germany), using our institutional protocol as previously described \[[@CR15]\]. For each patient, the sagittal abdominal diameter at the level of the portal vein bifurcation was measured on axial T1-weighted MR images in the portal-venous phase.

C-arm imaging system {#Sec5}
--------------------

The differences between the two platforms are new acquisition software protocols for DF and DSA that lower the X-ray flux, reducing the dose at the cost of decreased image quality, and a workstation with real-time image processing algorithms to recover for the loss in image quality. In detail, the new acquisition parameters consisted of a decreased tube voltage (75 vs 78 kVp), use of the smaller focal spot size (0.4 vs. 0.7 mm), additional 0.1 mm copper and 1 mm aluminium filters. Automatic tube current modulation was enabled on both imaging platforms. The real-time image processing algorithms were spatial noise reduction for DF and spatial noise reduction, temporal averaging and automatic pixel shift for DSA \[[@CR12]\].

Besides the new acquisition protocols and the real-time post processing, the two platforms are identical, using a dynamic 14-bit flat panel digital detector with an image matrix of 2480 × 1920 pixels, a pixel pitch of 154 × 154 μm and a maximum field of view of 30 × 38 cm.

The dose-saving features apply only to 2D imaging and so for CBCT, the acquisition parameters and the 3D reconstruction were identical for both C-arm imaging platforms. The acquisition parameters for CBCT were 120 kVp tube voltage, 5 ms exposure and 50 mA tube current, the last of these being modulated automatically during the acquisition. During 5.2 s of exposure, 312 projection images (60 frames/s) were acquired with the motorized C-arm covering a 240° clockwise arc at a rotation speed of up to 55°/s.

TACE protocol {#Sec6}
-------------

The indication for treatment and the choice of treatment modality were discussed at our multidisciplinary liver tumor board on a case-by-case basis. All TACE procedures were performed by the same interventional radiologist (JFG) with 18 years of experience in hepatic interventions. A standardized approach according to our institutional protocol was used \[[@CR16]\].

A dual-phase C-arm contrast-enhanced CBCT was acquired with the microcatheter placed in the hepatic artery branch considered to be the main tumour feeding vessel to verify correct positioning. After drug delivery, a single CBCT acquisition was performed to confirm technical success of embolization. Additional details of the CBCT protocols for identification of feedings arteries and assessment of treatment success have been reported previously \[[@CR14], [@CR15], [@CR17], [@CR18]\]. CBCTs were not acquired for a few patients who were unable to hold their breath since acquiring CBCTs with breathing motion would result in insufficient image quality and would have been of no clinical value.

Radiation exposure measurements and calculations {#Sec7}
------------------------------------------------

The new imaging platform (used for the study group) supported Digital Imaging and Communications in Medicine (DICOM) Radiation Dose Structured Reports (RDSR). RDSR contains detailed log information of every X-ray event, including radiation time, air kerma (AK), dose area product (DAP) and number of images acquired (see Appendix [1](#MOESM1){ref-type="media"}). A dedicated workstation was set up with DoseUtility (PixelMed Publishing, Bangor, PA) to receive, store and evaluate the RDSRs of the study group patients.

The old imaging platform (used for the control group) did not support RDSR, thus the examination reports generated by the system were used (see Appendix [2](#MOESM2){ref-type="media"}). These examination reports contained the AK and the DAP of the whole procedure as well as the cumulative DAP and radiation time of all DF runs. However, the DAP of all DSA and CBCT runs was combined into a single "Cumulative DAP (exposure)" on these examination reports (see Appendix [2](#MOESM2){ref-type="media"}). To separate DAP of DSA and CBCT, the DAP shown on-screen during the treatment before and after each CBCT scan was manually recorded. The DAP of each CBCT was calculated using the following formula:$$\documentclass[12pt]{minimal}
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The cumulative DAP of all DSA runs was calculated using the formula:$$\documentclass[12pt]{minimal}
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In addition, the examination reports provided only the number of images acquired and not the radiation time for DSA. Thus, the latter had to be calculated using the number of images acquired during each run and knowing the frame rate used. For example, 30 frames at a frame rate of 3 frames per second correspond to a radiation time of 10 s. To prove that all these calculations were correct, examination reports of five patients undergoing TACE on the new system were also collected, and the calculated values were found to be the same as the values recorded using RDSR.

To compensate for the differences in procedure complexity and thus in radiation time between the patients, the recorded and calculated DAP values were normalized to time by dividing by the corresponding radiation times for both DF and DSA runs. For example, the normalized DAP for 1 min of DF was calculated as DF Cumulative DAP(Gy cm^2^)/DF radiation time(min).

DF image quality assessment {#Sec8}
---------------------------

Objective DF image quality assessment was performed on an Osirix workstation (Pixmeo, Bernex, Switzerland) by an interventional radiologist (RES) with more than 4 years of clinical experience in liver imaging and TACE, who did not participate in the TACE procedures. For the assessment, a region of interest (ROI) with an area of 3 cm^2^ was placed in the abdomen, avoiding gas-filled intestines and bones, and the mean signal intensity and the standard deviation in Hounsfield units (HU) were recorded. A signal-to-noise ratio (SNR) was calculated using the formula SNR = mean HU/standard deviation HU. In addition, the signal intensity of the guidance wire in HU was recorded and a contrast ratio (CR) was calculated with the formula CR = mean HU/guidance wire HU.

DSA image quality assessment {#Sec9}
----------------------------

Qualitative DSA image analysis was performed by two interventional radiologists (RES and RD), each with more than 4 years of clinical experience in liver imaging and TACE, who did not participate in the TACE procedures. The DSA images of the celiac run of all patients were presented in a blinded and randomized fashion on an Osirix workstation. The readers were blinded to the imaging C-arm system used and the imaging parameters. The window/level settings used were maintained as the default settings in Osirix. Both readers determined independently in separate reading sessions the visibility of the hepatic arteries using a four-point grading score (Table [1](#Tab1){ref-type="table"}).Table 1Four-point grading score for the subjective assessment of DSA image qualityScoreDescription1Perfect visualization of all hepatic arteries including small intra-tumoral vessels2Visibility from the proper hepatic artery to the subsegmental branches3Visibility from the proper hepatic artery to the segmental branches4Visibility from the proper hepatic artery to the lobar arteries only

Statistical analysis {#Sec10}
--------------------

All statistical computations were performed in SPSS Statistics 22 (IBM Corp., Armonk, NY). A *p* value less than 0.05 was considered statistically significant. Descriptive statistics were performed to summarize the data. The distribution of all scale variables was assessed with the Shapiro--Wilk test. For scale variables with normal distribution, mean, standard deviation and range were used and an unpaired *t* test was performed. For scale variables with non-Gaussian distribution, median, interquartile range and range were used and a Wilcoxon rank-sum test was performed. For ordinal variables, count and percentage were used and a Wilcoxon rank-sum test was performed. Cohen's kappa was used to calculate inter-rater reliability.

Results {#Sec11}
=======

Patient demographics {#Sec12}
--------------------

Patients' baseline characteristics are summarized in Table [2](#Tab2){ref-type="table"}. There was no significant difference between the study and the control groups regarding age (*p* = 0.71), BMI (*p* = 0.95) and sagittal abdominal diameter of the patient at the level of the portal vein bifurcation (*p* = 0.69). Hepatocellular carcinoma was the most common cancer in both groups, tumour burden by means of lesion number and number of affected liver segments were similar (*p* = 0.49 and *p* = 0.34, respectively).Table 2Baseline characteristics of the study and the control groupsCharacteristicStudy groupControl group*p* valueNo. of patients52 (100)26 (100)Sex Female15 (29)5 (19) Male37 (71)21 (81)Age^a^60.3 ± 10.8 (33--79)61.3 ± 10.5 (33--80)0.71Body mass index^a^27.5 ± 5.9 (16.0--40.9)27.4 ± 6.1 (16.0--37.9)0.95Sagittal abdominal diameter at the level of the portal vein bifurcation (cm)^a^25.6 ± 4.1 (18.2--36.7)25.2 ± 4.0 (18.3--31.2)0.69Tumour type Hepatocellular carcinoma32 (61)20 (77) Intrahepatic cholangiocarcinoma3 (6)1 (4) Secondary liver cancer17 (33)5 (19)No. of lesions0.49 113 (25)9 (35) 28 (15)4 (15) 38 (15)4 (15)  \> 323 (45)9 (35)No. of segments affected0.34 1 or 224 (46)14 (54) 3 or 49 (17)3 (12)  \> 419 (37)9 (35)Except where indicated, data represent numbers of patients and numbers in parentheses are percentages^a^Data represented as mean ± standard deviation (range)

TACE procedures {#Sec13}
---------------

Procedure characteristics are summarized in Table [3](#Tab3){ref-type="table"}. Approximately half of the procedures were for TACE-naïve patients in both cohorts. Conventional TACE was performed in the majority of cases (56 % and 73 % of the study and control groups, respectively). However, only a minority of procedures were performed in a lobar fashion (21 % and 15 % of the study and control groups, respectively). The median DF time for study and control groups was 15.6 min (range 5.6--37.2) and 15.5 min (range 8.6--54.6), respectively. A median of 6 DSA runs was acquired in the study (range 3--11) and control (range 3--13) groups, respectively. The median DSA time for study and control groups was 71.5 s (range 17.4--167.4) and 63.9 s (range 24.4--204.2). A median of 3 CBCTs was acquired in the study (range 0--5) and control (range 0--6) groups, respectively. There were no statistically significant differences between the two groups regarding DF time (*p* = 0.34), DSA time (*p* = 0.66) as well as number of DSA and CBCT performed (*p* = 0.97 and *p* = 0.56, respectively).Table 3Procedure characteristics of the study and the control groupsCharacteristicStudy groupControl group*p* valueSequence no. of procedure0.62 125 (48)11 (42) 214 (27)7 (27) 35 (10)3 (12)  \> 38 (15)5 (19)Type of TACE Conventional TACE29 (56)19 (73) Drug-eluting beads TACE23 (44)7 (27)Selectivity of TACE Lobar11 (21)4 (15) Selective16 (31)10 (38) Superselective25 (48)12 (46)Catheter positions for drug delivery0.69 140 (77)19 (73) 212 (23)7 (27)DF time (min)^a^15.6; 9.8 (5.6--37.2)15.5; 11.0 (8.6--54.6)0.34No. of DSA acquisitions^a^6; 3.8 (3--11)6; 3.0 (3--13)0.97DSA time (s)^a^71.5; 48.0 (17.4--167.4)63.9; 35.3 (24.4--204.2)0.66No. of CBCT acquisitions^a^3; 2 (0--5)3; 1 (0--6)0.56Except where indicated, data represent numbers of patients and numbers in parentheses are percentages^a^Data represented as median; interquartile range (range)

Radiation exposure {#Sec14}
------------------

A detailed description of DAP and AK in terms of median, interquartile range, minimum and maximum is summarized for the study and the control groups in Table [4](#Tab4){ref-type="table"}, including the values normalized by radiation time. By switching to the new system, the cumulative DAP and the cumulative AK decreased by 66 % (from 395.8 to 132.9 Gy cm^2^) and 61 % (from 1.16 to 0.49 Gy), respectively. The DAP for DF and for exposure (DSA and CBCT) decreased by 52 % (from 99.6 to 47.8 Gy cm^2^) and 70 % (from 272.6 to 81.8 Gy cm^2^), respectively. The DAP reduction for CBCT was only 15 %, whereas for DSA it was 79 % (Fig. [1](#Fig1){ref-type="fig"}). After normalizing DF and DSA by the radiation time, the DAP for DF and DSA decreased by 47 % (from 6.4 to 3.4 Gy cm^2^/min) and 84 % (from 244.7 to 39.9 Gy cm^2^/min), respectively. In the control group, DF and DSA accounted for 27 % and 61 % of the cumulative DAP, respectively. In the study group, the contribution of DF increased to 38 %, whereas the contribution of DSA to the cumulative DAP decreased to 38 %. Most importantly, the relative contribution of CBCT to the cumulative DAP increased from 12 % to 24 % by switching to the new system. In other words, the radiation exposure of one CBCT was equivalent to 155 s DF or 4 s DSA in the control group and 247 s DF or 21 s DSA in the study group.Table 4Radiation exposure for the study and the control groupsStudy groupControl groupReduction*p* valueCumulative DAP (Gy cm^2^)132.9; 146.2 (30.7--588.4)395.8; 434.4 (86.2--1469.9)66 %\<0.01Cumulative AK (Gy)0.49; 0.52 (0.06--2.35)1.16; 1.18 (0.28--3.82)61 %\<0.01DF DAP (Gy cm^2^)47.8; 62.3 (9.4--288.6)99.6; 105.2 (28.3--307.4)52 %\<0.01DF DAP/min (Gy cm^2^/min)3.4; 3.7 (1.1--15.3)6.4; 5.2 (2.2--12.0)47 %\<0.01Exposure DAP (Gy cm^2^)81.8; 79.8 (10.2--380.1)272.6; 397.6 (58.0--1197.1)70 %\<0.01CBCT DAP for 1 CBCT (Gy cm^2^)14.0; 7.3 (4.7--21.2)16.5; 12.6 (5.2--22.8)15 %0.51Cumulative CBCT DAP (Gy cm^2^)30.5; 36.7 (0.0-103.7)44.8; 40.7 (0.0-82.4)32 %0.19DSA DAP (Gy cm^2^)48.8; 77.6 (3.0-316.7)228.4; 371.2 (42.4-1153.0)79 %\<0.01DSA DAP/min (Gy cm^2^/min)39.9; 42.5 (9.5--192.3)244.7; 237.9 (62.2--453.9)84 %\<0.01Data represented as median; interquartile range (range)Fig. 1Box plot showing the distribution of radiation exposure (dose area product in Gy cm^2^) for the study and the control groups for the entire procedure, for digital subtraction angiography, digital fluoroscopy and cone beam CT. The plot uses power scale on the y-axis and shows the interquartile range (*box*), 5th and 95th percentiles (*outermost bars*) and the median (*thick horizontal line*) of the exposure distribution in each system

DF image quality {#Sec15}
----------------

The SNR of the new platform was significantly higher than that of the old platform \[31.1 ± 6.0 (range 17.7--49.9) vs 23.2 ± 4.4 (range 15.7--31.8); *p* \< 0.01\]. The visibility of the guide wire expressed as CR on the other hand was significantly lower in the new platform \[1.74 ± 0.35 (range 1.27--2.63) vs 2.00 ± 0.30 (range 1.46--2.50); *p* ≤ 0.01\].

DSA image quality {#Sec16}
-----------------

There was no statistically significant difference regarding the image quality between the two cohorts according to both readers (*p* = 0.82 and *p* = 0.75, respectively) using the provided four-point grading score for the visibility of hepatic arteries. Both readers rated the majority of celiac arteriograms in both cohorts as perfect (category 1) (Fig. [2](#Fig2){ref-type="fig"}). No celiac arteriogram was rated as category 4 (Table [5](#Tab5){ref-type="table"}). Cohen's kappa showed a substantial agreement between both readers (κ = 0.76 and κ = 0.66 for the old and new platforms, respectively, *p* \< 0.01). A detailed distribution of image quality scores is shown in Table [5](#Tab5){ref-type="table"}.Fig. 2Celiac arteriogram during TACE in two patients with neuroendocrine tumour. *Left panel* was acquired on the preceding imaging platform and the *right panel* on the new imaging platform. Both arteriograms were of diagnostic quality, showing the tumour-feeding arteries and the tumour blush (*arrowheads*). However, the new imaging platform resulted in a significantly lower radiation exposure during the acquisition of the celiac arteriogramTable 5DSA Image quality score cross-tables of both readers for the study and the control groupsReader 1Total123Study group Reader 21304034241401830000 Total3418052Control group Reader 211720192040430123 Total177226

Discussion {#Sec17}
==========

The main finding of our study was the significant radiation exposure reduction of up to 66 % for the entire TACE procedure as a result of the new imaging platform. This significant reduction in radiation exposure is especially important in patients being treated repeatedly with TACE, in similar therapies such as radio-embolization, or as a bridging or downstaging prior to liver transplantation \[[@CR19]\]. Furthermore, the reduction in radiation exposure using the new system is also of importance for the in-room medical staff, because they are exposed to radiation on a regular basis.

Of note, the radiation exposure reduction was only significant for two-dimensional runs (such as DF and DSA) and not for CBCT acquisitions. This was expected as the dose reduction techniques in our work apply for 2D imaging only. The DSA runs showed the highest radiation exposure reduction of up to 84 %, and the exposure during DF and CBCT runs decreased by 47 % and 15 %, respectively. Thus, the relative impact of DSA on the cumulative DAP decreased from 61 % to 38 %, and the relative impact of DF and CBCT increased from 27 to 38 % and from 12 % to 24 %, respectively. Given the steady increase in the use of CBCT in TACE procedures because of its proven benefits \[[@CR20]--[@CR26]\], dose reduction for this imaging modality should be the next logical step to decrease cumulative radiation exposure even further.

Another important finding was that the image quality of DSA runs by means of subjective assessment of hepatic vessel visualization was not affected by the significant reduction of radiation exposure. For DF runs, the new platform showed a significantly improved SNR at the cost of a significantly decreased CR, in comparison to the old platform. However, the DF radiation time did not increase, clearly showing that this objectively measured difference in DF image quality did not have a negative impact on the course of TACE procedures. In other words, the image quality was still sufficient to continue the TACE procedure.

Comparison with other studies using absolute numbers is difficult because different metrics were used. Paul et al. \[[@CR27]\] used peak skin dose and DAP to compare three generations of angiographic imaging systems. These authors reported a radiation exposure reduction of 62 %, 15 % and 49 % for DF, DSA and CBCT during TACE procedures, respectively. The main reason for the significant reduction of CBCT DAP in their study was a faster CBCT acquisition protocol (3 vs. 8 s), which also resulted in fewer projection images being acquired (133 vs. 382 frames). However, their mean DAP for a CBCT run was 21.58 Gy cm^2^, whereas our CBCT protocol resulted in a median DAP of 13.9 Gy cm^2^ with 5.2 s of radiation time (the same acquisition protocol was used for both control and study imaging platforms). In addition, most studies do not normalize their exposure measurements by the radiation time, but only report radiation exposure and time as separate values. In our study, radiation exposure and time values were used together to calculate DF and DSA DAP for 1 min of radiation time each to normalize for differences in procedure complexity and to enable a better comparison with other studies. We report a median DF and DSA DAP per minute of 3.4 and 39.9 Gy cm^2^ on the new imaging platform, respectively. Calculating these normalized values for the previously mentioned study \[[@CR27]\], their mean DF and DSA DAP were 5.8 and 92.9 Gy cm^2^ on the latest generation of imaging platform used, respectively. This underlines the substantial radiation exposure reduction achieved by the new imaging platform used in our study.

Our study had several limitations. First, the number of patients included in the control group was limited to 26 by the upgrade of the imaging platform. However, even with a relatively small sample size of 78 patients, a statistically significant radiation exposure reduction was achieved while the study and the control groups did not show any significant differences in patient characteristics and in radiation time. Second, RDSR was not available for the preceding imaging platform, thus manual exposure logging had to be performed for all patients undergoing TACE on that platform and the DSA radiation time was calculated retrospectively using the number of images acquired during each DSA run. However, these calculations were verified by comparison to RDSR for a subset of patients examined on the new imaging platform.

In conclusion, the new imaging platform significantly reduced radiation exposure for TACE procedures without increased radiation time or negative impact on image quality.
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